Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $68 to $63.
byBenzinga Newsdesk
November 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $68 to $63.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts